Ozone Plasma on Lung Function and Inflammatory Parameters in Pulmonary Sequelae Associated With Coronavirus 19 Infection

• Status: Enrolling by invitation
• Trial end date: 2022-12-21
• Target enrollment: 0
• Participant gender: All

Summary

The risk for the development of complications from COVID-19 occurs mainly in patients over 65 years of age, with obesity, arterial hypertension, chronic lung diseases and immunosuppression states. Since the persistence of radiological imaging correlates with physiological deterioration, these patients are likely to be at increased risk of parenchymal lung disease.

It is known that the administration of Ozone, in any of the three phases of COVID-19 infection, is useful in the management of acute disease, both for its viricidal and anti-inflammatory activity, however, in the convalescence stage when the persistence of sequelae that can severely affect the quality of life of patients is identified.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centro Universitario de Ciencias de la Salud, Mexico

Criteria

Inclusion Criteria:

• Men and women

• 25-80 years

• Individuals without active disease with previous confirmed diagnosis of COVID-19 infection with negative nasopharyngeal PCR test

• With characteristic chest radiographic images compatible with lung infection, particularly interstitial pneumonitis with previous unburied glass patches, cobblestone or areas of consolidation (during active disease)

• Sign a letter of consent under information

Exclusion Criteria:

• Patients taking the following medicines: Ivermectin, azithromycin, corticosteroids, colchicine, chlorine dioxide, oral anticoagulants such as acenocoumarin, apixaban, rivaroxaban; bronchodilators such as β2-agonists such as salbutamol and derivatives, as well as inhaled anticholinergics of the ipratropium bromide type and derivatives.

• Patients who present medical difficulty or contraindication to perform the 6 km walk test in band

• Patients with a history of community-acquired pneumonia, pulmonary neoplasms, heart, renal, or hepatic failure